GlassScriptPhysician profile
Ora Frankel
NPI 1700072287
$6,224.87
in general payments reported to CMS, 2019-2025
31 companies · $709 in 2025
The $709 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $273 · 2021: $994 · 2022: $1,314 · 2023: $1,050 · 2024: $687 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,446.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $682.91 | 2021-2025 | |
| Lundbeck LLC | $676.17 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $645.56 | 2019-2025 | Wellbutrin, Aplenzin |
| Otsuka America Pharmaceutical, INC. | $530.81 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $328.41 | 2020-2025 | Caplyta |
| Alkermes, INC. | $307.30 | 2021-2025 | Lybalvi |
| Neurocrine Biosciences, INC. | $273.96 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $248.31 | 2020-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $237.34 | 2019-2022 | |
| Corium, LLC | $232.88 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $207.02 | 2019-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $205.53 | 2019-2025 | Spravato |
| Tris Pharma INC | $201.96 | 2019-2023 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $201.74 | 2019-2025 | Uzedy, Austedo, Austedo Xr |
| Jazz Pharmaceuticals INC. | $184.45 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $180.59 | 2019 | |
| Noven Therapeutics, LLC | $160.90 | 2023-2025 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $151.38 | 2019-2022 | |
| Axsome Therapeutics, INC. | $145.10 | 2022-2025 | Auvelity |
| Adlon Therapeutics L.P. | $64.71 | 2019-2021 | |
| Neos Therapeutics, LP | $56.30 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $51.28 | 2021-2023 | Qelbree |
| Almatica Pharma LLC | $43.58 | 2024 | Loreev Xr |
| Shire North American Group INC | $40.72 | 2019 | |
| Alfasigma USA, INC. | $36.39 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $27.76 | 2023 | Quviviq |
| Rhodes Pharmaceuticals L.P. | $24.49 | 2019 | |
| Mdd US Operations, LLC | $23.43 | 2020 | |
| Aytu Biopharma, INC. | $18.17 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.87 | 2025 | Jornay Pm |
| Neuronetics, INC. | $17.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ora Frankel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.